tirzepatide surmount 4 Demonstrates Sustained Weight Loss but Discontinuation Results in Weight Regain: SURMOUNT-4 Trial Just sharing the published Surmount

However, any changes to the dosing schedule should only be made under the guidance of a healthcare provider

Tell your healthcare provider if you have changes in vision during treatment with Zepbound

Latest developments on GLP-1 patches Various pharmaceutical companies, particularly in South Korea, including Daewoong Pharmaceutical, are working on developing microneedle patches for GLP-1 drugs

Participants who managed to keep their weight regain below 25% of lost weight showed a different pattern

Participants on CagriSema achieved a mean body weight reduction of approximately 15.6% from baseline substantially greater than either semaglutide or cagrilintide administered alone